LCP-Tacro tacrolimus: Phase III data

The open-label, international Phase III Study 3001 trial in 326 stable kidney transplant patients showed that once-daily LCP-Tacro met the primary endpoint of non-inferiority to twice-daily Prograf tacrolimus on a composite of death, graft failure, biopsy-proven acute rejection or loss to follow-up

Read the full 422 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE